MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
11.61
+1.11
+10.57%
After Hours: 11.69 +0.08 +0.69% 19:59 12/05 EST
OPEN
10.44
PREV CLOSE
10.50
HIGH
11.63
LOW
10.24
VOLUME
722.46K
TURNOVER
--
52 WEEK HIGH
20.37
52 WEEK LOW
2.880
MARKET CAP
416.28M
P/E (TTM)
-5.6876
1D
5D
1M
3M
1Y
5Y
1D
BioAge Labs Chief Medical Officer Paul D. Rubin Reports Disposal of Common Shares
Reuters · 1d ago
BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley
TipRanks · 1d ago
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD)
TipRanks · 2d ago
BioAge Labs Announces Positive Phase 1 Trial Results
TipRanks · 2d ago
BRIEF-Bioage Labs Inc - Announces Positive Interim Phase 1 Data For BGE-102
Reuters · 2d ago
BIOAGE LABS INC - ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR
Reuters · 2d ago
BioAge Labs announces interim Phase 1 data for BGE-102
TipRanks · 2d ago
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.